PCI Biotech to present poster at 4th Immunotherapy of cancer conference

Posted on Mar 21, 2017

Oslo, Norway, March 21, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present a poster of the fimaVacc technology at the 4th Immunotherapy of cancer conference (IOTC4) – the leading international conference providing a global platform in Europe for translational research in the field of immuno-oncology.

The event is taking place on Prague, Czech Republic, from 20 to 22 March 2017 and PCI Biotech will present a poster on 21 March, 17:30 local time (CET). The poster will be presented by Dr. Tone Otterhaug, Clinical Science Director.

The poster is named “Phase I clinical study for validation of photochemical internalisation (fimaVacc) – a novel technology for enhancing cellular immune responses important for therapeutic effect of peptide- and protein based vaccines.” and includes a brief technology background, preclinical results and plan for clinical translation through a phase I study in healthy volunteers. The initial study data on safety and tolerability indicates that intradermal treatment with fimaVACC is tolerated. Immune results with fimaVacc are expected to be available in first half of 2017.

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.


Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
www.pcibiotech.com
Ronny Skuggedal, CFO,
rs@pcibiotech.com , Mobile: +47 9400 5757.